Solesence, Inc. income statement
In fiscal 2025, Solesence, Inc. reported revenue of $62.1m, up 18.6% on the year before, operating income of $1.6m (a 2.5% margin) and net income of $1.8m, or $0.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 14 | 13 | 17 | 29 | 37 | 37 | 52 | 62 | 55 |
| Cost of revenue | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 9 | 11 | 10 | 11 | 21 | 29 | 29 | 36 | 46 | 41 |
| Gross profit | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 6 | 9 | 8 | 8 | 16 | 16 | 15 |
| Research and development | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 |
| Selling, general and administrative | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | 8 | 8 | 7 | 10 | 12 |
| Operating income | −4 | −3 | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −3 | 1 | 3 | −2 | −4 | 5 | 2 | −1 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | — | — |
| Income before tax | −4 | −3 | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −3 | 1 | 2 | −3 | −4 | 4 | 2 | −2 |
| Income tax | — | — | — | 0 | 0 | 0 | — | 0 | 0 | — | — | 0 | −0 | 0 | 0 | 0 | — |
| Net income | −4 | −3 | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −3 | 1 | 2 | −3 | −4 | 4 | 2 | −2 |
| Diluted EPS | −$0.19 | −$0.16 | −$0.10 | −$0.09 | −$0.06 | −$0.04 | −$0.04 | −$0.03 | −$0.06 | −$0.08 | $0.03 | $0.05 | −$0.05 | −$0.09 | $0.07 | $0.02 | −$0.03 |
| Diluted shares (average) | — | 21m | 24m | 28m | 28m | 29m | 31m | 31m | 34m | 37m | 39m | 47m | 49m | 50m | 65m | 73m | 72m |
| EBITDA | −3 | −2 | −1 | −2 | −1 | −0 | −1 | −0 | −2 | −2 | 2 | 3 | −2 | −3 | 6 | 2 | −0 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 13 | 15 | 20 | 15 | 12 | 13 | 15 |
| Cost of revenue | 11 | 10 | 11 | 14 | 11 | 9 | 10 | 11 |
| Gross profit | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 5 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 4 |
| Operating income | 3 | −0 | 0 | 2 | −1 | 0 | −1 | 0 |
| Interest expense | 0 | 0 | 0 | — | — | — | — | — |
| Income before tax | 3 | −0 | 0 | 4 | −1 | −0 | −1 | −0 |
| Income tax | — | — | — | 0 | 0 | −0 | — | — |
| Net income | 3 | −1 | 0 | 3 | −1 | 0 | −1 | −0 |
| Diluted EPS | $0.04 | −$0.01 | $0.00 | $0.04 | −$0.02 | $0.00 | −$0.01 | $0.00 |
| EBITDA | 3 | 0 | 0 | 3 | −1 | 0 | −0 | 0 |
Compare with peers
- Fitlife Brands, Inc. income statement
- Natural Health Trends Corp income statement
- Axil Brands, Inc. income statement
- Mannatech Inc income statement
- Cbdmd, Inc. income statement
Head to head: FTLF vs SLSNNHTC vs SLSNAXIL vs SLSN
More: Personal Care Products stocks compared, Consumer Staples sector, rankings of US companies